11/21
07:52 pm
fdmt
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript [Seeking Alpha]
11/20
08:12 am
fdmt
4DMT to Participate in 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
Medium
Report
4DMT to Participate in 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
11/20
08:00 am
fdmt
4DMT to Participate in 8th Annual Evercore Healthcare Conference
Medium
Report
4DMT to Participate in 8th Annual Evercore Healthcare Conference
11/17
06:00 am
fdmt
4DMT Appoints Kristian Humer as Chief Financial Officer
Low
Report
4DMT Appoints Kristian Humer as Chief Financial Officer
11/15
01:42 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by analysts at
Wall
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by analysts at
Wall
11/14
04:05 pm
fdmt
4DMT Announces New Employment Inducement Grants
Low
Report
4DMT Announces New Employment Inducement Grants
11/11
10:31 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its price target raised by analysts at Royal Bank Of Canada from $26.00 to $32.00. They now have an "outperform" rating on the stock.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its price target raised by analysts at Royal Bank Of Canada from $26.00 to $32.00. They now have an "outperform" rating on the stock.
11/11
08:16 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its price target raised by analysts at Chardan Capital from $25.00 to $26.00. They now have a "buy" rating on the stock.
Medium
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its price target raised by analysts at Chardan Capital from $25.00 to $26.00. They now have a "buy" rating on the stock.
11/11
07:03 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
11/10
08:16 am
fdmt
4D Molecular Therapeutics GAAP EPS of -$1.01 misses by $0.02 [Seeking Alpha]
Medium
Report
4D Molecular Therapeutics GAAP EPS of -$1.01 misses by $0.02 [Seeking Alpha]
11/10
08:11 am
fdmt
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones [Yahoo! Finance]
Medium
Report
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones [Yahoo! Finance]
11/10
08:00 am
fdmt
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Medium
Report
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
11/7
08:20 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating.
11/6
04:05 pm
fdmt
4DMT to Participate in Jefferies 2025 London Healthcare Conference
Low
Report
4DMT to Participate in Jefferies 2025 London Healthcare Conference
11/6
07:10 am
fdmt
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
11/6
07:10 am
fdmt
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years [Yahoo! Finance]
Low
Report
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years [Yahoo! Finance]
11/6
06:23 am
fdmt
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
Medium
Report
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
11/6
06:00 am
fdmt
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
Low
Report
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
10/31
11:03 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
10/30
11:02 pm
fdmt
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
Low
Report
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
10/21
10:50 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $26.00 price target on the stock.
Medium
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $26.00 price target on the stock.
10/17
04:05 pm
fdmt
4DMT Announces New Employment Inducement Grants
High
Report
4DMT Announces New Employment Inducement Grants
10/14
08:00 am
fdmt
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
Medium
Report
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
10/13
08:26 am
fdmt
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation [Yahoo! Finance]
Medium
Report
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation [Yahoo! Finance]
10/13
08:00 am
fdmt
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
Medium
Report
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation